Company intelligence / Profile preview
Xilio Therapeutics
Waltham, Massachusetts, United Statesxiliotx.com ↗
- Ownership
- Public · XLO
- Employees
- ~64
- Development stage
- Phase 2
01
Overview
Xilio’s lead program vilastobart/XTX101 has shown encouraging initial Phase II combination data in MSS colorectal cancer patients with a preliminary objective response rate of ~27% in patients without liver metastases. The safety profile appears differentiated with low immune-related adverse events (~5% colitis incidence). The company expects additional data updates through mid-to-late 2025.
The engineered cytokine program XTX301 is advancing through dose escalation and expansion cohorts without dose-limiting toxicities observed so far; further data expected by end of year.
The pipeline also includes novel masked T cell engager programs progressing preclinically as well as an upcoming IND filing planned for the bispecific PD1/IL2 candidate around mid–2026[1][3][5][6][10].
- Therapeutic areas
- Oncology
- Modalities
- Tumor-activated biologicsMasked bispecific antibodiesMasked T cell engagersEngineered cytokines (e.g., IL-2, IL-12)Fc-enhanced monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Major partnership announced early in Q1 of calendar year 2025 with AbbVie focused on developing novel tumor activated antibody-based immunotherapies including masked T cell engagers[7].
04
Financials
- Market cap
- $59M
- Total revenue
- $18.7M
- Enterprise value
- $-70.8M
Beyond the preview
Go deeper on Xilio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xilio Therapeutics.